009-A3

Alexza Pharmaceuticals, Inc. · Phase 1 active Small molecule

At a glance

Generic name	009-A3
Sponsor	Alexza Pharmaceuticals, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation (PHASE1)
Staccato Apomorphine Multi-dose PK and PD in Patients With Parkinson's Disease (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

009-A3 CI brief — competitive landscape report
009-A3 updates RSS · CI watch RSS
Alexza Pharmaceuticals, Inc. portfolio CI